BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21808129)

  • 1. Optimal duration of anticoagulation in patients with venous thromboembolism.
    Prandoni P; Piovella C; Spiezia L; Dalla Valle F; Pesavento R
    Indian J Med Res; 2011 Jul; 134(1):15-21. PubMed ID: 21808129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough?
    Prandoni P; Piovella C; Spiezia L; Dalla Valle F; Pesavento R
    Panminerva Med; 2012 Mar; 54(1):39-44. PubMed ID: 22278115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
    Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
    Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R
    Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal duration of anticoagulation in patients with unprovoked venous thromboembolism: the impact of novel anticoagulants.
    Prandoni P; Milan M; Sarolo L; Zanon E; Bilora F
    Int Angiol; 2017 Oct; 36(5):395-401. PubMed ID: 27982558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism.
    Prandoni P
    Adv Exp Med Biol; 2017; 906():89-100. PubMed ID: 27620306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
    Kreidieh F; Temraz S
    Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
    Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A
    Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.
    Verhovsek M; Douketis JD; Yi Q; Shrivastava S; Tait RC; Baglin T; Poli D; Lim W
    Ann Intern Med; 2008 Oct; 149(7):481-90, W94. PubMed ID: 18838728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study.
    Palareti G; Cosmi B; Legnani C; Antonucci E; De Micheli V; Ghirarduzzi A; Poli D; Testa S; Tosetto A; Pengo V; Prandoni P;
    Blood; 2014 Jul; 124(2):196-203. PubMed ID: 24879813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The optimal duration of anticoagulant treatment following pulmonary embolism].
    Couturaud F
    Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of anticoagulation after isolated pulmonary embolism.
    Palareti G; Cosmi B; Antonucci E; Legnani C; Erba N; Ghirarduzzi A; Poli D; Testa S; Tosetto A; Pengo V; Prandoni P;
    Eur Respir J; 2016 May; 47(5):1429-35. PubMed ID: 26917615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis.
    Prandoni P; Vedovetto V; Ciammaichella M; Bucherini E; Corradini S; Enea I; Cosmi B; Mumoli N; Visonà A; Barillari G; Bova C; Quintavalla R; Zanatta N; Pedrini S; Villalta S; Camporese G; Testa S; Parisi R; Becattini C; Cuppini S; Pengo V; Palareti G;
    Thromb Res; 2017 Jun; 154():35-41. PubMed ID: 28407492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current criteria to determine the duration of anticoagulant therapy].
    Palareti G
    Recenti Prog Med; 2007 Dec; 98(12):603-6. PubMed ID: 18369033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How D-dimer assay can be useful in deciding the duration of anticoagulation after venous thromboembolism: a review.
    Palareti G
    Expert Rev Hematol; 2015 Feb; 8(1):79-88. PubMed ID: 25348806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
    Palareti G; Legnani C; Cosmi B; Valdré L; Lunghi B; Bernardi F; Coccheri S
    Circulation; 2003 Jul; 108(3):313-8. PubMed ID: 12847064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients.
    Obi AT; Tignanelli CJ; Jacobs BN; Arya S; Park PK; Wakefield TW; Henke PK; Napolitano LM
    J Vasc Surg Venous Lymphat Disord; 2019 May; 7(3):317-324. PubMed ID: 30477976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Optimal duration of anticoagulation of venous thromboembolism].
    Savina EN; Couturaud F
    J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.